Skip to main content
. 2012 Dec 21;18(47):6987–6995. doi: 10.3748/wjg.v18.i47.6987

Table 3.

Multivariate analysis for risk factors of virologic breakthrough

HR 95%CI P value1
HBeAg (+) 3.251 0.400-26.403 0.270
Albumin (g/dL) 0.552 0.194-1.573 0.266
ALP (IU/L) 1.004 0.994-1.014 0.427
PT (INR) 1.269 0.186-8.648 0.808
Platelet (× 103/mm3) 0.997 0.986-1.007 0.519
Cirrhosis 1.016 0.243-4.448 0.983
Duration of prior lamivudine treatment (mo) 0.99 0.945-1.038 0.691
Inadequate response2 6.57 –1.517-28.458 0.012
Treatment groups3 0.029
Group B vs group A 0.668 0.149-2.984 0.597
Group C vs group A 0.096 0.015-0.629 0.015
1

P-values were calculated with Cox’s proportional hazard model; Variables with a P < 0.1 in the univariate analysis were included in the multivariate analysis;

2

Inadequate response was defined as serum HBV DNA levels of 2000 IU/mL or greater at 6 mo of treatment;

3

Treatment groups were divided into three groups according to the timing of the drug combination; groups A and B represent the patients who followed or violated the roadmap treatment strategy, respectively; group C included those participants who were treated by adding adefovir dipivoxil (adefovir) to ongoing lamivudine therapy. Roadmap treatment strategy was supposed to initiate adefovir monotherapy first and then add lamivudine later when serum HBV DNA levels were detectable (≥ 60 IU/mL) at six months of treatment. HBeAg: Hepatitis B e antigen; ALP: Alkaline phosphatase; PT: Prothrombin time; INR: International normalized ratio; HR: Hazard ratio.